trisomy 21 | GenomeWeb

trisomy 21

SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.

The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.

In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.

The companies reached an exclusive deal to provide Natera's Panorama NIPT in the Indian market. 

NEW YORK (GenomeWeb) – Mount Sinai Services today announced a distribution deal with Illumina to offer the Verifi non-invasive prenatal test in Ontario.

NEW YORK (GenomeWeb News) – The New York Department of Health has approved Ariosa Diagnostics to offer its non-invasive prenatal test to state residents, the company said today.

NEW YORK (GenomeWeb News) – Natera today announced a US distribution deal with pathology services provider ProPath for Natera's Panorama non-invasive prenatal screening test.

NEW YORK (GenomeWeb News) – Natera today announced that New York has issued a permit for the company's CLIA laboratory, allowing Natera to offer its preconception and prenatal tests to expecting parents in the state.

This article has been updated from a previous version to include information provided by a Novartis spokesperson.

NEW YORK (GenomeWeb News) – DASA Group and Natera have reached a deal to offer Natera's non-invasive prenatal diagnostic test in Brazil, the companies announced on Thursday.
Financial and other terms were not disclosed.

Pages

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.